Protara Therapeutics Inc (TARA)
2.88
-0.11
(-3.68%)
USD |
NASDAQ |
May 23, 10:23
Protara Therapeutics SG&A Expense (Quarterly): 4.103M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.103M |
| December 31, 2023 | 4.66M |
| September 30, 2023 | 4.482M |
| June 30, 2023 | 4.893M |
| March 31, 2023 | 4.589M |
| December 31, 2022 | 5.003M |
| September 30, 2022 | 4.508M |
| June 30, 2022 | 5.621M |
| March 31, 2022 | 5.605M |
| December 31, 2021 | 6.219M |
| Date | Value |
|---|---|
| September 30, 2021 | 6.737M |
| June 30, 2021 | 6.905M |
| March 31, 2021 | 6.54M |
| December 31, 2020 | 5.305M |
| September 30, 2020 | 5.266M |
| June 30, 2020 | 4.796M |
| March 31, 2020 | 7.095M |
| December 31, 2019 | 1.804M |
| September 30, 2019 | 1.256M |
| June 30, 2019 | 0.442M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.442M
Minimum
Jun 2019
7.095M
Maximum
Mar 2020
4.791M
Average
4.948M
Median
SG&A Expense (Quarterly) Benchmarks
| AngioDynamics Inc | 35.98M |
| Regulus Therapeutics Inc | 2.786M |
| Bio-Path Holdings Inc | 1.407M |
| Outset Medical Inc | 32.49M |
| NovaBay Pharmaceuticals Inc | 3.346M |